Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Forrester

- PMLiVE

Pfizer snaps up Biohaven’s migraine drug for $1.24bn

Pfizer will sell the migraine drug outside the US and will also gain the rights to a second drug

- PMLiVE

Delivering outcomes-led solutions with connected capabilities

Founded in 2007, Lucid Group has grown from a small UK-based medical education agency to a global healthcare consultancy and employs over 400 people with several offices in the UK...

Lucid Group Communications Limited

- PMLiVE

Pfizer’s oral antiviral Paxlovid significantly cuts risk of severe COVID-19

Pfizer has halted its phase 2/3 trial of its new antiviral combo Paxlovid after analysis shows it cuts the risk of hospitalisation or death from COVID-19 by nearly 90%

Data-driven healthcare communications

Data analysis is everywhere, and the role it plays in our lives is increasing exponentially. From deciding what car to purchase to what medicine will be prescribed for us, the...

Lucid Group Communications Limited

- PMLiVE

Pfizer’s 2021 revenue predictions soar to $82bn

Strong third-quarter revenues of $24.1bn lifted by sales of its BioNTech-partnered COVID-19 vaccine Comirnaty see Pfizer raise its 2021 revenue guidance to $82bn

Artificial Intelligence for Improving Patient Outcomes & Operational Efficiency

Jim Havelka, Founder & CEO of InformAI, discusses how AI can be used to improve medical diagnoses, patient treatment plans, outcome predictions, hospital risk mitigation, and operational efficiencies. He also...

Impetus Digital

- PMLiVE

AZ’s Imfinzi boosts survival in biliary tract cancer

Positive results for Imfimzi plus chemotherapy offer hope for patients with a rare and aggressive gastrointestinal cancer

- PMLiVE

Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19

Results from the world’s first randomised, controlled COVID-19 vaccine booster trial show a third dose of Pfizer-BioNTech’s Comirnaty offers near-total protection from infection

- PMLiVE

Valneva COVID-19 vaccine more effective than AZ

Valneva will seek regulatory approval in the UK and European Union after its COVID-19 vaccine candidate performed well in phase 3 trials

- PMLiVE

AZ’s Imfinzi combination shows promise in liver cancer

Combining Imfinzi with experimental monoclonal antibody tremelimumab improved overall survival in patients with the most common form of liver cancer

- PMLiVE

Future focus: 3 tools for launching fast in the face of uncertainty

Dan Twibell, Head of Commercial Strategy, Consulting at Fishawack Health, reveals 3 fundamental tools for lean biotechs approaching a rapid launch. He gives his advice on how to manage resources...

Avalere Health

- PMLiVE

Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death

The antibody is the only long-acting combination shown to both prevent and treat COVID-19

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links